With Bristol-Myers Squibb Co.’s largest institutional investor revealing that it opposes the $74bn acquisition of Celgene Corp. and a recently engaged activist investor trying to build a strong case against the combination, several analysts nonetheless say the proposed deal – facing an April 12 shareholder vote – still has sufficient momentum to go through.
Celgene/Bristol: Happy Union Or Runaway Bride?
Wellington, the largest institutional shareholder in Bristol, and activist firm Starboard both have publicly opposed the Bristol/Celgene merger but the strong crossover of investors in both biopharmas suggests the deal will still obtain approval.

More from Deals
The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
The companies will co-develop the drug for additional indications beyond Huntington’s disease, while Prilenia retains rights in key global markets.
The German group is paying $3.9bn to get hold of the US firm and its two approved products.
More from Business
The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.
Merck is investing $ 1bn in a Delaware facility to produce Keytruda and expand biologics manufacturing amid US tariff concerns.
Europe's biopharma sector could suffer if the Trump administration incentivizes US investment but VC leaders believe the region can still thrive and potentially capitalize on instability elsewhere.